Author: Gábor Márk Somfai (Switzerland)
Co-authors: Cengiz Türksever, Susanne Oesch, Tobias Machewitz, Sandrine Zweifel, Pascal W. Hasler
Purpose
The purpose of this analysis was to explore functional and anatomic outcomes (best-corrected visual acuity [BCVA] and central retinal thickness [CRT]) in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) who were treated with intravitreal aflibercept (IVT-AFL) for up to 104 weeks, but who were identified retrospectively as meeting criteria for a hypothetical switch at Week 24.
Setting/Venue
This post hoc analysis was based on patient data from ARIES (NCT02581891): a randomized, open-label, active-controlled, Phase 3b/4 study that compared the efficacy of two different proactive, individualized treat-and-extend (T&E) regimens of IVT-AFL.
Methods
In ARIES, patients received three initial monthly doses of 2 mg IVT-AFL, followed by an injection after an 8-week treatment interval (Week 16). At Week 16, patients were randomized 1:1 to early-start T&E (IVT-AFL T&E from Week 16 adjusted in 2-week steps) or late-start T&E (IVT-AFL every 8 weeks until Week 48, then T&E from Week 48) with a maximum treatment interval of 16 weeks. Anatomic criteria for extending treatment intervals were the absence of intraretinal fluid (IRF), absence of new neovascularization or hemorrhage, and subretinal fluid (SRF) not exceeding 50 µm in thickness. The primary endpoint of the study was change in BCVA (Early Treatment Diabetic Retinopathy Study [ETDRS] letters) from randomization (Week 16) to Week 104. This post hoc analysis was conducted to describe BCVA and CRT up to Week 104 in patients in the early-start T&E arm who did and did not meet the criteria for a hypothetical switch at Week 24. Criteria for switch, based on clinical practice, were the presence of IRF and/or SRF with central involvement and a next planned treatment interval of ≤8 weeks at Week 24.
Results
In the per-protocol set (n=106), 41 patients (baseline: BCVA, 60.6 letters; CRT, 464.8 μm) met the criteria for a hypothetical switch at Week 24 and 65 patients did not (baseline: BCVA, 60.0 letters; CRT, 453.4 μm). In the switch group, at Week 24, SRF with central involvement was present in 33/41 (80.5%) patients and IRF with central involvement was present in 12/41 (29.3%) patients. Mean (95% CI) change in BCVA from baseline at Week 24 was +6.1 (3.4, 8.8) letters in patients meeting switch criteria and +6.6 (4.7, 8.6) letters in patients not meeting switch criteria; changes at Week 52 were +8.2 (5.0, 11.3) and +7.5 (5.3, 9.7) letters, respectively, and at Week 104 were +5.7 (1.3, 10.1) and +3.4 (0.1, 6.7) letters. Mean (95% CI) change in CRT from baseline in patients who did and did not meet switch criteria was ‒152.0 (‒186.1, ‒117.9) and ‒173.1 (‒203.5, ‒142.6) μm, respectively, at Week 52, and ‒138.3 (‒175.7, ‒101.0) and ‒176.2 (‒212.0, ‒140.4) μm, respectively, at Week 104.
Conlusions
In ARIES, patients with nAMD who could have hypothetically switched anti-VEGF treatment, initial improvements in BCVA were maintained with continued proactive, individualized T&E IVT-AFL therapy. Our results suggest that there is limited rationale for switching treatment-naïve nAMD patients on IVT-AFL during the early course of the therapy since, with continuous proactive treatment, comparable visual gains can be achieved by these patients compared with those who initially respond well on a T&E regimen. As the ARIES study follow-up was 104 weeks, further long-term studies are needed to determine the relevance of our findings over a longer time period.
Financial Disclosure
Gábor Márk Somfai: Consultant for Allergan, Bayer, and Novartis Cengiz Türksever: Consultant for Allergan, Bayer, and Novartis Susanne Oesch: Employee of Bayer (Schweiz) AG Tobias Machewitz: Employee of Bayer AG Sandrine Zweifel: Consultant: Bayer Healthcare Pharmaceuticals, Novartis Pharma AG, and Roche Diagnostics; Speaker: Bayer Healthcare Pharmaceuticals, and Novartis Pharma AG Pascal W. Hasler: Speaker: Bayer, Novartis, and Topcon
Comments
-